CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ¾ÈÀçö
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : ºñ°ú(ÄÚÁúȯ)/ÄÚ°ñÀÌ/¼ö¸é/¼Ò¾ÆÆíµµ¾Æµ¥³ëÀ̵å/Ãà³óÁõ/¾Ë·¹¸£±âºñ¿°
  • Á÷ À§: Á¶±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
272 (±¹¿Ü)SCI Enhanced intervertebral disc repair via genetically engineered mesenchymal stem cells with tetracycline regulatory system
271 (±¹¿Ü)SCI Risk of Subsequent Primary Cancer in Thyroid Cancer Survivors: A Nationwide Population-Based Study
270 (±¹¿Ü)SCI Longitudinal study of the inverse relationship between Parkinson¡¯s disease and cancer in Korea
269 (±¹¿Ü)SCI Association between the Use of Statins and Brain Tumors
268 (±¹¿Ü)SCI Frey syndrome after conservative parotidectomy: Importance of closing the remnant parotid parenchyma
267 (±¹¿Ü)SCI Epigenetic modulation of ferroptosis in cancer: Identifying epigenetic targets for novel anticancer therapy
266 (±¹¿Ü)SCI Relation of Statin Use with Esophageal Cancer
265 (±¹¿Ü)SCI Targeting Nrf2 for ferroptosis-based therapy: Implications for overcoming ferroptosis evasion and therapy resistance in cancer
264 (±¹¿Ü)SCI Nrf2 targeting in overcoming ferroptosis evasion in head and neck cancer
263 (±¹¿Ü)SCI Unleashing Ferroptosis in Human Cancers: Targeting Ferroptosis Suppressor Protein 1 for Overcoming Therapy Resistance
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 6 7 8 9 10 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729